Our Mission

At Countagen, we are molecular biologists and biotechnologists working to remove a critical bottleneck in cell and gene therapy development: scalable, reliable gene-edit characterization.

LockSeq was built to reduce genomic blind spots caused by target dropout, amplification-related bias, and sequencing noise. By combining one-probe-per-target capture with UMI-based consensus sequencing, LockSeq enables quantitative characterization of gene-editing outcomes at scale—revealing genomic blind spots earlier, converting them into actionable safety evidence, and reducing late-stage development risk. 

.